Failed early
Cannabidiol: improve symptoms or function in MS (type not specified)
MS (type not specified) · Spasticity
Controlled phase 2 trials were negative.
- Trials
- 3
- Running now
- 2
- Controlled phase 2/3 trials
- 1
- People in controlled trials
- 448
Deciding trials (phase 2): 0 met, 1 did not.
Other linked trials: 2
Dose comparisons, trials against another medicine, add-on trials, phase 1 and uncontrolled studies. They are listed below but do not set the status.
Trials
- The effect of medical cannabis on neuropathic pain and spasticity in patients with MS and SCIdecides the statusMissed main goal
Phase 2 · 2018 · Placebo-controlled · MSFT-2018-002315-98
Nevertheless, in this four-arm parallel trial, no effect was found between placebo and active treatment with THC or CBD alone or in combination on NP or spasticity in patients with either MS or SCI.
Read by software from the paper's abstract
Other linked trials: 2
These linked trials do not set the status.
Phase 2 · 2025 · Not randomised
Phase 2 · 2022 · Compared with dronabinol
The deciding phase and counts come from the Trial Bank’s fixed rules.
Lab evidence
Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.
Loading lab studies…
Loading reviews and guidelines…
History
- 2026-10-28First listed as Failed early
Related hypotheses
- Spasticity: improve symptoms or function in MS (type not specified)
- Arbaclofen: improve symptoms or function in MS (type not specified)
- Baclofen: improve symptoms or function in MS (type not specified)
- Botulinum toxin type a: improve symptoms or function in MS (type not specified)
- Cannabidiol: improve symptoms or function in relapsing and progressive MS
- Dronabinol: improve symptoms or function in MS (type not specified)
- Nabilone: improve symptoms or function in MS (type not specified)
- Nabiximols: improve symptoms or function in MS (type not specified)
- Onabotulinumtoxina: improve symptoms or function in MS (type not specified)
- Rimabotulinumtoxinb: improve symptoms or function in MS (type not specified)
- Tizanidine: improve symptoms or function in MS (type not specified)
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error